GlassScriptPhysician profile
John Gancayco
NPI 1609089390
$1,767.37
in general payments reported to CMS, 2019-2025
24 companies · $1,642 in 2025
The $1,642 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $125 · 2025: $1,642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,767.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $333.22 | 2025 | |
| Janssen Biotech, INC. | $228.02 | 2025 | Tremfya |
| Phathom Pharmaceuticals, INC. | $200.17 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $166.91 | 2025 | Rezdiffra |
| Echosens North America, INC. | $157.26 | 2025 | Fibroscan |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.19 | 2025 | Xifaxan, Relistor |
| Aimmune Therapeutics, INC. | $98.89 | 2025 | Vowst, Zenpep |
| Takeda Pharmaceuticals U.S.A., INC. | $94.99 | 2025 | Entyvio, Eohilia, Gattex |
| Genzyme Corporation | $68.86 | 2025 | |
| Lilly USA, LLC | $64.25 | 2025 | Omvoh |
| Pfizer INC. | $40.87 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $38.13 | 2025 | Dupixent |
| Celltrion USA INC. | $36.99 | 2025 | Vegzelma |
| Ardelyx, INC. | $29.54 | 2025 | Ibsrela |
| Braintree Laboratories, INC. | $23.75 | 2025 | Sutab, Suflave |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $21.23 | 2025 | Sucraid |
| Gilead Sciences, INC. | $17.93 | 2025 | |
| Novo Nordisk INC | $17.23 | 2025 | Wegovy |
| Evoke Pharma, INC. | $15.44 | 2025 | |
| Azurity Pharmaceuticals, INC. | $13.50 | 2025 | Suflave |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Gancayco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.